Corcept Therapeutics Company Profile: Stock Performance & Earnings

Corcept Therapeutics Overview

Founded
1998

Status
Public

Employees
206

Stock Symbol
CORT

Share Price
$28.14
(As of Friday Closing)

Corcept Therapeutics General Information

Description

Corcept Therapeutics Inc is engaged in the discovery, development, and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders by modulating the effects of cortisol.

Contact Information

Website

www.corcept.com

Ownership Status

Publicly Held

Financing Status

Formerly VC-backed

Primary Industry

Pharmaceuticals

Stock Exchange

NAS

Primary Office

149 Commonwealth Drive
Menlo Park, CA 94025
United States

+1 (650) 000-0000





Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Corcept Therapeutics Stock Performance

(As of Friday Closing)

Stock Price	Previous Close	52 wk Range	Market Cap	Shares	Average Volume	EPS
$28.14	$27.62	$9.70 - $28.36	$3.27B	116M	939K	$0.96

Corcept Therapeutics Financials Summary

In Thousands, USD	TTM 30-Sep-2020	FY 2019 31-Dec-2019	FY 2018 31-Dec-2018	FY 2017 31-Dec-2017
EV	1,609,428	1,151,922	1,347,509	1,985,926
Revenue	356,034	306,486	251,247	159,201
EBITDA	134,944	113,777	89,732	52,961
Net Income	109,398	94,181	75,410	129,122
Total Assets	534,125	412,312	311,694	220,537
Total Debt	3,031	3,461	0	0

Public Fundamental Data provided by Morningstar, Inc. disclaimer

Corcept Therapeutics Valuation & Funding

Deal Type	Date	Amount	Valuation/ EBITDA	Post-Val	Status	Debt

This information is available in the PitchBook Platform. To explore Corcept Therapeutics‘s full profile, request access.

Request a free trial

Corcept Therapeutics Comparisons

Description

Primary
Industry

HQ Location

Employees

Total Raised

Post Valuation

Last Financing Details

Corcept Therapeutics Inc is engaged in the discovery, development, and commercialization of drugs for the treatment of s

Pharmaceuticals

Menlo Park, CA

206 As of 2019

00000

00000000000 00000

0000 000

or sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna

0000000000000

Cambridge, MA

000 As of 0000

00.000

000000000 00.000

00000000

quip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum

0000000000000

Pasadena, CA

000 As of 0000

00.000

000000 - 000 00.000

Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Corcept Therapeutics Competitors (16)

Company Name	Financing Status	Location	Employees	Total Raised	Last Financing Date/Type	Last Financing Amount
SAGE Therapeutics	Formerly VC-backed	Cambridge, MA	000	00.000	000000000	00.000
000000000 00000000	Corporation	Pasadena, CA	000	00.000	000000 - 000	00.000
000000000000	Formerly VC-backed	South San Francisco, CA	000	00000	000000000	00000
000000000 00000000	Formerly VC-backed	Cambridge, MA	00	00000	000000 - 000	00000
00000000 000000000	Formerly VC-backed	Ann Arbor, MI	000	00000	00000000000	00000

You’re viewing 5 of 16 competitors. Get the full list »

Corcept Therapeutics Executive Team (7)

Name	Title	Board Seat	Contact Info
Joseph Belanoff MD	Chief Executive Officer & Founder
Charles Robb JD	Chief Financial Officer
Hazel Hunt Ph.D	Director, Research
Daniel Bradbury	Independent Director

You’re viewing 4 of 7 executive team members. Get the full list »

Corcept Therapeutics Board Members (9)

Name	Representing	Role
Daniel Swisher Jr.	Self	Board Member
David Mahoney	Self	Board Member
George Baker Jr.	Self	Board Member
Gregg Alton JD	Corcept Therapeutics	Board Member
James Wilson	Self	Chairman & Board Member